Non-Small Cell Lung Cancer Surgical Management

On this page

Quick Reference

RxDrug of choiceAdjuvant osimertinib 80 mg daily for 3 years for resected EGFR-mutated (ex19del/L858R) stage IB-IIIA NSCLC.

AltAlternativesPlatinum-based chemotherapy (cisplatin + vinorelbine) for stage II-IIIA without driver mutations; adjuvant atezolizumab for PD-L1 TC ≥1%; adjuvant ensartinib for ALK-positive; adjuvant selpercatinib for RET fusion-positive.

⊘AvoidBevacizumab with concurrent thoracic radiation (increases tracheoesophageal fistula risk). Non-dihydropyridine calcium channel blockers are not relevant here, but avoid concurrent immunotherapy with certain conditions (e.g., active autoimmune disease).

DxTest of choiceCombined EBUS-TBNA + EUS-FNA for mediastinal staging (sROC 0.99). PET/CT for distant staging. Pulmonary function tests (FEV1, DLCO) for fitness assessment.

ScKey scoreClinical TNM stage (AJCC 8th edition) is the primary determinant of resectability and adjuvant therapy triggers.

→When to referRefer to thoracic surgery for any patient with stage I-IIIA NSCLC who is medically operable. Refer to medical oncology for neoadjuvant or adjuvant therapy discussion. Refer to radiation oncology for unresectable stage III or for patients who decline surgery.

Surgical resection (preferably via VATS or RATS) is curative for early-stage NSCLC. Neoadjuvant chemo-immunotherapy is now standard for stage II-IIIA, and adjuvant targeted therapy dramatically improves outcomes in driver-mutation-positive patients. Accurate staging, patient fitness, and multidisciplinary care are essential.

Non-small cell lung cancer (NSCLC) surgical management covers indications by stage, operative techniques, fertility-sparing options, sentinel lymph node mapping, adjuvant therapy triggers, intraoperative complications, postoperative recovery via ERAS, and outcomes. This concise reference prioritizes actionable clinical data for bedside use, preserving all citation numbers and wikilinks.

Overview and Recommendations

Background

•Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers, and surgical resection remains the only potentially curative therapy for localized disease. Stage I disease achieves 5-year survival rates exceeding 70% after complete (R0) resection, making early detection and operative intervention critical.
•Surgical eligibility is determined by clinical stage (TNM), histologic subtype, molecular profile, and patient fitness. Stage I-IIIA(N2) disease is generally resectable with curative intent, while stage IIIB(N3) and stage IV are typically treated with definitive chemoradiation or systemic therapy alone.
•The paradigm of surgical management has shifted from upfront surgery alone to a multimodality approach. For stage II-IIIA, neoadjuvant or perioperative chemo-immunotherapy is now standard, superseding surgery-first strategies. This change is driven by trials showing improved event-free survival and pathologic complete response rates.
•Molecular subtypes (EGFR, ALK, RET) strongly influence adjuvant therapy decisions. For resected EGFR-mutated NSCLC, adjuvant osimertinib 80 mg daily for 3 years improves 4-year disease-free survival from 29% to 70%. Similarly, adjuvant ensartinib 225 mg daily for 24 months dramatically improves outcomes in ALK-positive disease.
•Minimally invasive approaches, video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracoscopic surgery (RATS), have become the standard for early-stage NSCLC, offering reduced pain, shorter hospital stay, and equivalent oncologic outcomes compared with open thoracotomy.

Evaluation

•Suspect surgical candidacy in any patient with a new lung nodule or mass on imaging. Begin with a thorough history: smoking history, performance status, comorbidities (especially COPD, heart disease), and prior thoracic surgery.
•Examine for signs of advanced disease: supraclavicular lymphadenopathy, hoarseness (recurrent laryngeal nerve), pleural effusion, or weight loss. These may indicate unresectable disease.
•Order contrast-enhanced CT chest through the adrenal glands for initial staging. PET/CT is essential for detecting nodal and distant metastases. Brain MRI is recommended for stage II-IV disease to rule out brain metastases.
•Perform mediastinal staging with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and/or endoscopic ultrasound (EUS) for all patients with suspected N2/N3 disease. Combined EBUS+EUS has a diagnostic accuracy of 0.99, comparable to mediastinoscopy.
•Assess cardiopulmonary fitness: pulmonary function tests (FEV1, DLCO), cardiac stress testing if coronary artery disease is suspected, and exercise capacity. The 8-week smoking cessation threshold is critical, it reduces postoperative pulmonary complications (OR 0.42).
•Evaluate frailty using the Veterans Affairs Frailty Index, which strongly predicts major complications (adjusted OR 2.85). Consider formal prehabilitation (exercise, nutrition, anxiety reduction) for high-risk patients starting 4 weeks before surgery.
•Determine resectability based on clinical stage: Stage I (T1-2aN0) is resectable; Stage II (T1-2bN1, T3N0) is resectable with neoadjuvant therapy; Stage IIIA (N2) is selectively resectable after induction therapy; Stage IIIB (N3) is unresectable.
•Obtain molecular testing (EGFR, ALK, RET, PD-L1) on biopsy tissue. Results guide neoadjuvant treatment decisions (e.g., osimertinib for EGFR-mutated) and adjuvant therapy planning.
•Multidisciplinary team discussion (thoracic surgery, medical oncology, radiation oncology, pulmonology, pathology) is mandatory before any treatment decision. This ensures optimal sequencing and avoids inappropriate surgery.

Management

•For stage IA NSCLC, perform lobectomy with systematic mediastinal lymph node sampling or dissection. For ground-glass opacity (GGO)-dominant invasive adenocarcinoma ≤3 cm and consolidation-to-tumor ratio ≤0.5, systematic mediastinal lymph node dissection can be safely omitted, it does not improve survival and increases operative time and blood loss.
•For stage IA with small peripheral tumors (≤2 cm), consider segmentectomy as an alternative to lobectomy. The pooled hazard ratio for overall survival in stage IA is 1.10 (favoring lobectomy) but not statistically significant, so sublobar resection is reasonable in selected patients.
•For stage IB with tumors ≥4 cm, consider adjuvant platinum-based chemotherapy (e.g., cisplatin plus vinorelbine). CALGB 9633 showed a significant survival benefit for tumors ≥4 cm (HR 0.69). For stage IB <4 cm, no adjuvant therapy is indicated.
•For stage II-IIIA, administer neoadjuvant chemo-immunotherapy (e.g., platinum doublet plus nivolumab, pembrolizumab, or tislelizumab). This is the preferred approach over upfront surgery. The RATIONALE-315 trial showed perioperative tislelizumab plus chemotherapy improved overall survival (HR 0.65) and event-free survival (HR 0.58).
•For resected stage II-IIIA without driver mutations, give adjuvant cisplatin-based chemotherapy (e.g., cisplatin 75 mg/m² day 1 + vinorelbine 25 mg/m² days 1 and 8, every 3 weeks for 4 cycles). The LACE pooled analysis showed a 4% absolute improvement in 5-year survival.
•For resected EGFR-mutated (exon 19 deletion or L858R) stage IB-IIIA, prescribe adjuvant osimertinib 80 mg orally once daily for 3 years. The ADAURA trial demonstrated a 4-year DFS of 70% versus 29% with placebo (HR 0.23).
•For resected ALK-positive stage IB-IIIB, prescribe adjuvant ensartinib 225 mg orally once daily for 24 months. The ELEVATE trial showed 24-month DFS of 86.4% versus 53.5% (HR 0.20).
•For resected RET fusion-positive stage II-IIIA, prescribe adjuvant selpercatinib for 3 years (dose per package insert). The LIBRETTO-432 trial showed 2-year EFS of 92% versus 61% (HR 0.17).
•For stage II-IIIA with PD-L1 TC ≥1% after chemotherapy, consider adjuvant atezolizumab 1200 mg IV every 3 weeks for 16 cycles. IMpower010 showed DFS benefit (HR 0.70), with pronounced benefit in PD-L1 ≥50% (OS HR 0.47).
•For stage IB-IIIA regardless of PD-L1, pembrolizumab 200 mg IV every 3 weeks for up to 18 cycles is an alternative (PEARLS/KEYNOTE-091), but it is not yet standard for all subgroups.
•Perform surgery using minimally invasive approach (VATS or RATS) whenever possible. RATS offers higher lymph node yield and lower conversion rates than VATS, especially after neoadjuvant therapy. Uniportal VATS has shorter hospital stay and lower conversion than multiportal VATS.
•For central tumors requiring pneumonectomy, consider bronchial sleeve lobectomy to preserve lung parenchyma. RATS for sleeve lobectomy is associated with shorter operative time and less blood loss than open thoracotomy.
•During surgery, ensure adequate lymph node assessment: sample at least 3 N2 stations and 1 N1 station (the 3+1 rule). This is safe and does not increase complications.
•Use ERAS protocols: multimodal analgesia, early mobilization, and coaxial chest drains. Coaxial drains reduce drainage duration (4 vs 6 days) and tube occlusion (4% vs 30%).
•Avoid concurrent bevacizumab with thoracic radiation, it increases the risk of tracheoesophageal fistula (two phase II trials closed early). Consider proton beam therapy when radiation is needed to reduce esophageal toxicity.
•Refer to medical oncology for all patients with stage II-IIIA disease to discuss neoadjuvant and adjuvant therapy. Refer to radiation oncology for stage IIIB (unresectable) or for patients with N2 disease in whom definitive chemoradiation is preferred.
•Discharge criteria: chest tube removed with no air leak, pain controlled on oral analgesics, mobilized independently, and afebrile. Follow-up imaging scheduled at 3-6 months postoperatively.

Board Review — High Yield

•GGO-dominant invasive adenocarcinoma, Systematic mediastinal lymph node dissection can be safely omitted (ECTOP-1009 trial).
•Stage IB adjuvant chemotherapy, Only indicated for tumors ≥4 cm (CALGB 9633).
•Neoadjuvant chemo-immunotherapy, Standard of care for stage II-IIIA NSCLC; improves event-free survival and pathologic response.
•Osimertinib adjuvant, 80 mg daily for 3 years in EGFR-mutated resected NSCLC; 4-year DFS 70% vs 29% (ADAURA).
•Ensartinib adjuvant, 225 mg daily for 24 months in ALK-positive resected NSCLC; 2-year DFS 86.4% vs 53.5% (ELEVATE).
•Atezolizumab adjuvant, For PD-L1 TC ≥1% stage II-IIIA after chemotherapy; OS HR 0.47 in PD-L1 ≥50% (IMpower010).
•EBUS+EUS mediastinal staging, sROC 0.99, recommended as first-line over mediastinoscopy (ERS/ESGE/ESTS).
•Conversion to thoracotomy, Higher after neoadjuvant therapy (20% MIS); RATS has lower conversion rate than VATS.
•8-week smoking cessation, Threshold for reducing postoperative pulmonary complications (OR 0.42, specificity 96.55%).
•Coaxial chest drains, Reduce drainage duration, tube occlusion, and subcutaneous emphysema after VATS lobectomy.

Deep Dive — Evidence Details

Indications by Stage

▸Stage IA GGO-dominant can omit mediastinal LND.
▸Neoadjuvant chemo-immunotherapy preferred for stage II-IIIA.

HY High Yield: For stage IB, only tumors ≥4 cm warrant adjuvant chemotherapy.

Surgical eligibility for NSCLC is determined by stage and patient fitness. Stage I: lobectomy with systematic mediastinal lymph node sampling is standard. For GGO-dominant T1N0M0 invasive adenocarcinoma, systematic mediastinal LND can be safely omitted (ECTOP-1009) ^[15]^A1b. Stage IB: consider adjuvant chemotherapy only if tumor ≥4 cm (CALGB 9633) ^[16]^A1b. Stage II: neoadjuvant/perioperative chemo-immunotherapy is preferred (meta-analysis HR 0.69 for EFS) ^[7]^A1a; RATIONALE-315 confirmed perioperative tislelizumab plus chemotherapy improved OS (HR 0.65) ^[9]^A1b. Stage IIIA(N2): selectively resectable after induction therapy; for EGFR-mutated, neoadjuvant osimertinib improves R0 resection (NeoADAURA) ^[12]^A1b; for ALK-positive, adjuvant ensartinib improves DFS (ELEVATE) ^[19]^A1b. Stage IIIB(N3): unresectable, treat with definitive chemoradiation + durvalumab ^[17]^C4. Stage IV: surgery only for oligometastatic disease.

Stage	Resectability	Preferred Surgical Approach	Perioperative Systemic Therapy	Key Evidence [Ref]
IA (T1a-cN0)	Yes	Lobectomy or (GGO-dominant: omit mediastinal LND)	Not indicated	^[15]^A1b
IB (T2aN0)	Yes	Lobectomy	Consider adjuvant chemotherapy if tumor ≥4 cm	^[16]^A1b
IIA-IIB	Yes	Lobectomy or	Neoadjuvant chemo-immunotherapy or adjuvant chemotherapy	^[7]^A1a^[9]^A1b^[10]^A1b
IIIA (N2)	Selectively resectable	Lobectomy after induction therapy	Neoadjuvant chemo-immunotherapy; adjuvant targeted therapy if EGFR/ALK+	^[4]^A1c^[7]^A1a^[12]^A1b
IIIB (N3)	Unresectable	None	Definitive chemoradiation +	^[17]^C4
IV	Rarely (oligometastatic)	Metastasectomy ± primary resection	Systemic therapy	,

Pearl: For GGO-dominant T1N0M0 invasive lung adenocarcinoma, systematic mediastinal lymph node dissection is unnecessary and may cause harm, omit it ^[15]^A1b. For resected stage II-IIIA NSCLC, neoadjuvant/perioperative chemo-immunotherapy is now the standard of care, superseding upfront surgery ^[7]^A1a.

Operative Techniques

▸Endosonography first-line for mediastinal staging.
▸Sublobar resection acceptable for select stage IA.

! Warning: Negative EBUS-TBNA after induction has NPV only 20%; confirm with surgical staging.

Accurate mediastinal staging via EBUS-TBNA + EUS-FNA provides sROC 0.99, comparable to mediastinoscopy ^[33]^B2a. ERS/ESGE/ESTS recommends endosonography as first-line ^[29]^A1c. For restaging after induction, negative EBUS-TBNA has NPV only 20%; confirm with surgical staging ^[38]^D5. For stage I, lobectomy vs sublobar: pooled HR for OS 1.09 (95% CI 1.02-1.16) favoring lobectomy, but for stage IA not significant (HR 1.10) ^[27]^A1a. Minimally invasive: RATS yields higher lymph node yield than VATS ^[35]^B2a; uniportal VATS has shorter hospital stay and lower conversion rate (3.3% vs 5.1%) ^[36]^B2a. Sleeve lobectomy avoids pneumonectomy; RATS shows advantages ^[37]^B2a. Neoadjuvant ICI increases hilar fibrosis; RATS may lower conversion ^[25]^A1b. Controversy: endosonography vs mediastinoscopy - endosonography preferred initial test; mediastinoscopy reserved for negative endosonography ^[33]^B2a.

Question	Position A	Position B	Strength	Implication
Mediastinal staging: endosonography vs mediastinoscopy	ERS/ESGE/ESTS recommends endosonography as first-line ^[29]^A1c	Brazilian Group of Thoracic Oncology states mediastinoscopy remains surgical gold standard ^[33]^B2a	High-quality evidence for both	Endosonography is preferred initial test; mediastinoscopy reserved for negative endosonography ^[33]^B2a
Lobectomy vs sublobar for stage IA	Pooled HR for OS not significant (HR 1.10, 95% CI 0.99-1.22) ^[27]^A1a	Individual meta-analyses show significant OS benefit for lobectomy in broader stage I	Low certainty	Sublobar resection acceptable for select patients with stage IA; shared decision-making needed

Pearl: For patients with stage IIIA-N2 disease who have negative endosonography after induction therapy, always confirm with surgical staging before thoracotomy, the negative predictive value of EBUS-TBNA is only 20% ^[38]^D5.

Diagnostic Accuracy of Mediastinal Staging Modalities

Modality	sROC	Sensitivity	Specificity	PPV	NPV	Accuracy
EBUS-TBNA + EUS-FNA	0.99	NR	NR	NR	NR	NR
EBUS-TBNA alone	0.98	76%*	100%*	100%*	20%*	77%*
EUS-FNA alone	0.96	NR	NR	NR	NR	NR
CT	0.73	NR	NR	NR	NR	NR
PET-CT	0.87	NR	NR	NR	NR	NR

*Values from ^[38]^D5 for restaging after induction chemotherapy. NR = not reported in the source. sROC values from ^[33]^B2a.

Sentinel Lymph Node Mapping

▸Negative SLN has 100% NPV for nodal disease.
▸Upstaging in 12-23% of cases.

HY High Yield: Negative SLN with rigorous pathology has 100% NPV for downstream nodal metastases.

SLN mapping improves staging precision. Techniques: 99mTc-MSA detection rate 96-97% ^[69]^C4; 68Ga-MSA PET/CT 100% ^[62]^B2b; ICG NIR fluorescence with doses ≥1000 μg yields ~90% visualization ^[66]^C4; navigational bronchoscopy-guided ICG 80% detection, 100% sensitivity/specificity ^[61]^B2b. Accurate injection yields 100% SLN identification ^[72]^C4. Negative SLN has 100% NPV for downstream nodal disease ^[61]^B2b^[62]^B2b^[72]^C4. Upstaging occurs in 12.5-23.5% ^[61]^B2b^[62]^B2b. Factors: female sex and DLCO>75% predict detection; severe emphysema negative ^[74]^C4. Long-term: pN0 SLN associated with 100% 5-year DFS vs 66.1% ^[65]^C4. Controversy: SLN mapping vs systematic LND not yet in guidelines.

Technique	Tracer	Injection Timing	SLN Detection Rate	Key Finding	Reference
SPECT/CT	99mTc-nanocolloid	Pre-operative	50%	Limited visualization; pleural/systemic activity common	^[60]^C4
PET/CT	68Ga-MSA	Pre-operative	100%	No false-negative SLN in N1/N2 patients	^[62]^B2b
NIR fluorescence	ICG (≥ 1000 μg)	Intra-operative	~90%	SLN status correlated with final nodal status	^[66]^C4
NIR + NB-guided	ICG	Intra-operative	80%	12.5% upstaging rate; 100% NPV for nodal status	^[61]^B2b
NIR (transpleural/transbronchial)	ICG	Intra-operative	100% (accurate injection)	Negative SLN predictive of no downstream metastases	^[72]^C4

Pearl: When performed with accurate peritumoral tracer injection and rigorous pathologic evaluation (serial sectioning and cytokeratin staining), a negative SLN has a 100% negative predictive value for downstream nodal disease, providing confidence in stage I designation and potentially guiding the omission of adjuvant therapy.

Adjuvant Therapy Triggers

▸Adjuvant osimertinib for EGFR-mutated stage IB-IIIA.
▸Adjuvant immunotherapy based on PD-L1 and stage.

Rx Drug of Choice: Osimertinib 80 mg daily × 3 years for resected EGFR-mutated NSCLC.

Adjuvant therapy based on stage and biomarkers. Stage IB ≥4 cm: consider platinum chemo (CALGB 9633) ^[16]^A1b. Stage II-IIIA: cisplatin-based chemo standard (LACE, ANITA) ^[10]^A1b^[88]^A1b. For EGFR-mutated: osimertinib 80 mg/day × 3 years (ADAURA: 4-year DFS 70% vs 29%) ^[11]^A1b; aumolertinib similar ^[89]^A1b. ALK-positive: ensartinib 225 mg/day × 24 months (ELEVATE: 24-month DFS 86.4% vs 53.5%) ^[19]^A1b. RET fusion: selpercatinib × 3 years (LIBRETTO-432: 2-year EFS 92% vs 61%) ^[85]^A1b. Immunotherapy: atezolizumab after chemo for PD-L1 TC ≥1% (IMpower010) ^[13]^A1b; pembrolizumab for stage IB-IIIA regardless of PD-L1 (PEARLS) ^[20]^A1b. PORT not recommended for N2 (Lung ART) ^[86]^A1b.

Stage / Biomarker	Recommended Adjuvant Therapy	Key Evidence	NNT (if reported)
IB (≥4 cm)	Consider platinum-based chemotherapy	CALGB 9633 ^[16]^A1b	Not calculable
II-IIIA (no driver)	Cisplatin-based chemotherapy (e.g., vinorelbine + cisplatin)	LACE ^[10]^A1b, ANITA ^[88]^A1b	25
EGFR-mutated (ex19del/L858R), stage IB-IIIA	Osimertinib 80 mg/day × 3 years	ADAURA ^[11]^A1b	Not calculable
EGFR-mutated (ex19del/L858R), stage II-IIIB	Aumolertinib 110 mg/day × 3 years	ARTS ^[89]^A1b	Not calculable
ALK-positive, stage IB-IIIB	Ensartinib 225 mg/day × 24 months	ELEVATE ^[19]^A1b	Not calculable
RET fusion-positive, stage II-IIIA	Selpercatinib × 3 years	LIBRETTO-432 ^[85]^A1b	Not calculable
PD-L1 TC ≥1%, stage II-IIIA	1200 mg q3w × 16 cycles after chemotherapy	IMpower010 ^[13]^A1b	Not calculable
PD-L1-unselected, stage IB-IIIA	200 mg q3w × up to 18 cycles	PEARLS/KEYNOTE-091 ^[20]^A1b	Not calculable

Pearl: For stage IB NSCLC, only tumors ≥4 cm warrant adjuvant chemotherapy; the strongest absolute benefit from adjuvant therapy is seen in EGFR-mutated patients receiving osimertinib (4-year DFS 70% vs 29%) and in PD-L1 TC ≥50% stage II-IIIA patients receiving atezolizumab (OS HR 0.47).

Intraoperative Considerations and Complications

▸Smoking cessation ≥8 weeks reduces complications.
▸RATS reduces conversion risk.

! Warning: Avoid concurrent bevacizumab with thoracic radiation due to tracheoesophageal fistula risk.

Intraoperative complications after neoadjuvant chemoimmunotherapy: pooled incidence 3% ^[92]^A1a. Bleeding leading cause of conversion; MIS conversion rate 20% after neoadjuvant ^[92]^A1a; RATS reduces conversion vs VATS (OR 2.47) ^[97]^B2b. Prolonged air leak >4 days: 14% VATS, 9% thoracotomy ^[90]^A1b. Bronchopleural fistula 2% ^[93]^B2b. Recurrent laryngeal nerve injury 2% ^[99]^C4. Tracheoesophageal fistula increased with bevacizumab + radiation ^[91]^B2b; proton beam reduces esophagitis ^[93]^B2b. Preoperative smoking cessation ≥8 weeks reduces pulmonary complications (OR 0.42) ^[96]^B2b. Frailty (VA Frailty Index) predicts major complications (OR 2.85) ^[106]^B3b. RATS learning curve plateau at cases 82-137 with 10.7% complications ^[95]^B2b. Lymph node dissection (3+1 rule) not associated with increased complications ^[102]^B3b.

Complication	Frequency	Prevention	Management
Intraoperative bleeding	3% (neoadjuvant ICI) ^[92]^A1a; lower with RATS vs VATS ^[104]^B3b	Careful hilar dissection, vascular control, early conversion threshold	Emergent thoracotomy, suture repair, damage control packing
Conversion to thoracotomy	20% MIS after neoadjuvant ICI ^[92]^A1a; VATS 7.7% vs RATS 0.9% ^[104]^B3b	Patient selection, robotic platform, experienced surgeon	Standard thoracotomy, complete resection within same setting
Prolonged air leak (>4 days)	14% VATS, 9% thoracotomy ^[90]^A1b	Fissureless technique, stapler reinforcement, pleural tent	Chest tube management, Heimlich valve, pleurodesis (talc or blood patch)
Bronchopleural fistula	2% grade 4 (proton beam) ^[93]^B2b	Bronchial stump coverage, avoid devascularization	Reoperation, muscle flap, Eloesser flap
Tracheoesophageal fistula	Increased with bevacizumab + radiation ^[91]^B2b; grade 3-4 esophagitis 29% ^[94]^C4	Avoid concurrent bevacizumab with radiation; proton beam therapy	Esophageal stent, surgical repair, diversion
Recurrent laryngeal nerve injury	2% (subcostal RATS) ^[99]^C4	Avoid excessive traction near aortopulmonary window	Voice therapy, temporary vocal cord injection
Arrhythmia	~1% (VATS and thoracotomy) ^[90]^A1b	Minimize thoracic epidural, correct electrolytes	Beta-blockers, if
Chronic pleural effusion (1 year)	9.7% ^[101]^C4	Complete lung expansion, early chest tube removal?	Associated with non-cancer mortality; manage underlying wasting

Pearl: The 8-week smoking cessation threshold (96.55% specificity) is a critical inflection point for reducing postoperative pulmonary complications, and frailty assessment using the VA Frailty Index identifies patients at highest risk of major intraoperative and postoperative events ^[96]^B2b^[106]^B3b.

Postoperative Recovery and ERAS

▸ERAS reduces LOS and complications.
▸Coaxial drains improve outcomes.

HY High Yield: Coaxial drains reduce drainage duration and tube occlusion.

ERAS pathways reduce length of stay (7 to 5 days) and cardiopulmonary complications by 13% ^[121]^B3b. Coaxial chest drains reduce drainage duration (4 vs 6 days), tube occlusion (4% vs 30%), and subcutaneous emphysema ^[110]^A1b. Low negative pressure drainage ball reduces pain and stay ^[111]^A1b. Acute postoperative pain occurs in ~20%; nomogram predicts risk (AUC 0.760) ^[118]^B3b. Multimodal prehabilitation 4 weeks before surgery effective ^[107]^A1b. Readmission after VATS wedge: 10.1% ^[116]^B2b. Prognostic factors: coaxial drain, no preoperative analgesics, never smoker, younger age, no prior thoracic surgery, low anxiety, female sex, preserved lung function, no pleural adhesions, non-NSCLC diagnosis, ERAS implementation.

Factor	Good prognosis	Poor prognosis
Chest drain type	Coaxial drain ^[110]^A1b	Conventional tube ^[110]^A1b
Preoperative analgesic use	None ^[118]^B3b	Yes ^[118]^B3b
Smoking history	Never ^[118]^B3b	Current/former ^[118]^B3b
Age	Younger ^[118]^B3b	Older (>55) ^[118]^B3b
Prior thoracic surgery	No ^[118]^B3b	Yes ^[118]^B3b
Anxiety	Low ^[118]^B3b	High ^[118]^B3b
Sex	Female ^[116]^B2b^[119]^C4	Male ^[116]^B2b^[119]^C4
Lung function	Preserved ^[119]^C4	Reduced ^[119]^C4
Pleural adhesions	Absent ^[119]^C4	Present ^[119]^C4
NSCLC diagnosis	Benign/metastasis ^[119]^C4	NSCLC ^[119]^C4
ERAS pathway	Implemented ^[121]^B3b	Not implemented ^[121]^B3b

Pearl: Coaxial chest drains and ERAS pathways independently reduce drainage duration and length of stay; combining them optimizes recovery after VATS lobectomy.

Outcomes by Stage and Approach

▸Advanced NSCLC survival improved with immunotherapy/targeted therapy.
▸Sex and histology modify ICI efficacy.

HY High Yield: Pembrolizumab monotherapy for PD-L1 ≥50% advanced NSCLC: median OS 26.3 vs 13.4 mo.

Long-term outcomes after NSCLC resection depend on stage and adjuvant therapy. For advanced NSCLC, modern systemic therapies show substantial OS improvements: KEYNOTE-024 (pembrolizumab vs chemo: median OS 26.3 vs 13.4 mo, HR 0.62) ^[136]^A1b; KEYNOTE-189 (pembrolizumab + chemo: OS 22.0 vs 10.7 mo, HR 0.56) ^[138]^A1b; CheckMate 227 (nivolumab + ipilimumab: 5-year OS 24% vs 14% for PD-L1 ≥1%) ^[137]^A1b; CROWN (lorlatinib vs crizotinib: 5-year PFS 60% vs 8%) ^[134]^A1b. Prognostic factors: severe lymphopenia after chemoradiation (HR 2.1) ^[130]^B2a; sex modifies ICI efficacy (men HR 0.72, women 0.86) ^[144]^A1a; histology matters (Dato-DXd benefit in nonsquamous only) ^[133]^A1b. Controversy: pembrolizumab monotherapy vs nivolumab+ipilimumab+chemo for PD-L1 ≥50% - both standard.

Trial	Regimen	Median OS	Hazard Ratio	5-Year OS Rate	Population
KEYNOTE-024 ^[136]^A1b	vs. chemo	26.3 vs. 13.4 mo	0.62 (0.48-0.81)	31.9% vs. 16.3%	PD-L1 ≥50%
KEYNOTE-189 ^[138]^A1b	Pembrolizumab + pemetrexed-platinum vs. placebo + chemo	22.0 vs. 10.7 mo	0.56 (0.45-0.70)	Not reported	Nonsquamous, any PD-L1
CheckMate 227 ^[137]^A1b	+ vs. chemo	5-yr OS 24% vs. 14% (PD-L1 ≥1%); 19% vs. 7% (PD-L1 <1%)	Not applicable	24% vs. 14% (PD-L1 ≥1%)	PD-L1 ≥1% and <1%
CheckMate 9LA ^[146]^A1b	Nivolumab + ipilimumab + chemo vs. chemo	6-yr OS 16% vs. 10%	0.74 (0.63-0.87)	16% vs. 10% at 6 yr	Any PD-L1, any histology
CROWN (lorlatinib) ^[134]^A1b	Lorlatinib vs. crizotinib	Median PFS not reached vs. 9.1 mo	0.19 (0.13-0.27) for PFS	60% vs. 8% at 5 yr	ALK+ advanced
TROPION-Lung01 ^[133]^A1b	Dato-DXd vs.	12.9 vs. 11.8 mo	0.94 (0.78-1.14)	Not reported	Previously treated, nonsquamous histology benefited
RATIONALE-307 ^[145]^A1b	+ chemo vs. chemo	HR 0.68 (0.46-1.01) and 0.75 (0.50-1.12)	Not significant	Not reported	Squamous, first-line

Pearl: For advanced NSCLC, the survival benefit of modern immunotherapy- and targeted therapy-based regimens is substantial, and these outcomes should be discussed with patients when considering surgical resection for early-stage disease, as the curability of surgery remains the primary determinant of long-term survival, with 5-year OS rates exceeding 60% in resected stage I disease, though the provided evidence does not report these specific surgical outcomes.

References

[1]
Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗
L1GUIDELINECited in: Indications by Stage, Intraoperative Considerations and Complications
[2]
Jazieh AR, Bamefleh H, Demirkazik A et al.. “Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697125 ↗
L1GUIDELINECited in: Indications by Stage
[3]
Brodowicz T, Ciuleanu T, Crawford J et al.. “Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21940784 ↗
L1GUIDELINECited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[4]
Eberhardt WE, De Ruysscher D, Weder W et al.. “2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25897013 ↗
L1GUIDELINECited in: Indications by Stage
[5]
Vansteenkiste J, Crinò L, Dooms C et al.. “2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24562446 ↗
L1GUIDELINECited in: Indications by Stage
[6]
Cavalheri V, Tahirah F, Nonoyama M et al.. “Exercise training for people following lung resection for non-small cell lung cancer - a Cochrane systematic review.” Cancer treatment reviews (2013). PMID: 24268442 ↗
L1SR_MA_RCTCited in: Indications by Stage
[7]
Rossi G, Barcellini L, Tagliamento M et al.. “Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.” ESMO open (2025). PMID: 40913837 ↗
L1SR_MA_RCTCited in: Indications by Stage
[8]
Felip E, Altorki N, Zhou C et al.. “Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37467930 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[9]
Wang C, Wang W, Liu H et al.. “Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41344593 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[10]
Le Chevalier T. “Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20943614 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[11]
Herbst RS, Wu YL, John T et al.. “Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36720083 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[12]
He J, Tsuboi M, Weder W et al.. “Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40454705 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[13]
Felip E, Altorki N, Zhou C et al.. “Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40446184 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[14]
Awad MM, Forde PM, Girard N et al.. “Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39778121 ↗
L1RCTCited in: Indications by Stage
[15]
Zhang Y, Qian B, Song Q et al.. “Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40690727 ↗
L1RCTCited in: Indications by Stage
[16]
Strauss GM, Herndon JE, Maddaus MA et al.. “Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18809614 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[17]
Allignet B, De Ruysscher D, Martel-Lafay I et al.. “Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.” Cancer treatment reviews (2023). PMID: 37210766 ↗
L4SR_COHORTCited in: Indications by Stage
[18]
Wink KCJ, van Baardwijk A, Troost EGC et al.. “Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.” Cancer treatment reviews (2017). PMID: 28437679 ↗
L2SR_COHORTCited in: Indications by Stage
[19]
Yue D, Huang M, Song P et al.. “Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicine (2026). PMID: 42418775 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[20]
O'Brien M, Paz-Ares L, Marreaud S et al.. “Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36108662 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria)
[21]
Kanwar N, Seyi AB, Tan N et al.. “From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671451 ↗
L4CASE_SERIESCited in: Operative Techniques
[22]
Thomas A, Rajan A, Lopez-Chavez A et al.. “From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23131389 ↗
L5NARRATIVE_REVIEWCited in: Operative Techniques
[23]
Donington J, Schumacher L, Yanagawa J. “Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34985938 ↗
L5NARRATIVE_REVIEWCited in: Operative Techniques
[24]
Fang W, Wang Y, Wang W et al.. “Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.” JAMA surgery (2026). PMID: 42455561 ↗
L1RCTCited in: Operative Techniques
[25]
Magouliotis DE, Androutsopoulou V, Cioffi U et al.. “Robotic-Assisted Thoracic Surgery in the Immunotherapy Era: Navigating Altered Anatomy, Oncologic Precision, and the Future of Integrated Platforms.” Journal of clinical medicine (2026). PMID: 42355653 ↗
L1RCTCited in: Operative Techniques
[26]
Morrow CJ, Trapani F, Metcalf RL et al.. “Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27013395 ↗
L4CASE_SERIESCited in: Operative Techniques
[27]
Lin X, Zhang J, Wang B et al.. “Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes.” Frontiers in oncology (2026). PMID: 42326346 ↗
L1SR_MA_RCTCited in: Operative Techniques
[28]
Marinello A, Tagliamento M, Pagliaro A et al.. “Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer.” Cancer treatment reviews (2024). PMID: 38963991 ↗
L5NARRATIVE_REVIEWCited in: Operative Techniques
[29]
Korevaar DA, Kovacevic B, Papadopoulou E et al.. “ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.” The European respiratory journal (2026). PMID: 42167778 ↗
L1GUIDELINECited in: Operative Techniques
[30]
Babel S, Baral S, Peeran SRH et al.. “Systematic review of extracellular vesicle-based liquid biopsy for leptomeningeal metastasis: current evidence and future directions.” Clinical & experimental metastasis (2026). PMID: 42484930 ↗
L2SR_COHORTCited in: Operative Techniques, Fertility-Sparing Surgery
[31]
Yu YH, Huang YP, Yu AB et al.. “Perioperative outcomes and nodal station assessment after robotic-assisted versus video-assisted thoracoscopic segmentectomy for early-stage NSCLC: a systematic review and meta-analysis.” Journal of robotic surgery (2026). PMID: 42474630 ↗
L2SR_COHORTCited in: Operative Techniques, Intraoperative Considerations and Complications
[32]
Anosike UG, Oliveira Amador WF, Cruz de Assis TC et al.. “Outcomes of robotic vs video-assisted thoracoscopic segmentectomy in early-stage NSCLC: A meta-analysis of propensity-matched studies.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42456640 ↗
L4SR_COHORTCited in: Operative Techniques
[33]
Baldotto C, Mascarenhas E, Gelatti ACZ et al.. “Staging Modalities in Non-Small Cell Lung Cancer: Evidence-Based Guideline and Systematic Review by the Brazilian Group of Thoracic Oncology.” Clinical lung cancer (2026). PMID: 42114171 ↗
L2SR_COHORTCited in: Operative Techniques
[34]
Zhang C, Jiang BY, Yan LX et al.. “Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China.” EClinicalMedicine (2026). PMID: 42256683 ↗
L2NON_RANDOMIZED_TRIALCited in: Operative Techniques
[35]
Zhu J, Meng X, Hu L. “Perioperative outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer: a meta-analysis focusing on real-world clinical studies in the past 10 years.” Frontiers in oncology (2026). PMID: 42232542 ↗
L2SR_COHORTCited in: Operative Techniques
[36]
Wilson-Smith AR, Ali A, Bebawi M et al.. “Comparative outcomes of uniportal and multiportal video-assisted thoracoscopic surgery-a systematic review and meta-analysis.” Journal of thoracic disease (2026). PMID: 42182625 ↗
L2SR_COHORTCited in: Operative Techniques
[37]
Wang C, Qiao L, Xu Y et al.. “Robotic Surgery for Bronchial Sleeve Lobectomy: A Systematic Review and Bayesian Network Meta-Analysis.” The international journal of medical robotics + computer assisted surgery : MRCAS (2026). PMID: 42140880 ↗
L2SR_COHORTCited in: Operative Techniques, Intraoperative Considerations and Complications
[38]
Herth FJ, Annema JT, Eberhardt R et al.. “Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18519953 ↗
L5OTHERCited in: Operative Techniques
[39]
Bu F, Jin ZY, Ling ZQ. “Plasma HERV-K envelopE RNA: a minimally invasive biomarker for lung adenocarcinoma detection and prognostic assessment in the context of conventional serum tumor markers.” Frontiers in immunology (2026). PMID: 42459690 ↗
L2PROSPECTIVE_COHORTCited in: Operative Techniques
[40]
Feng S, Feng Z, Xie S et al.. “Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.” Journal for immunotherapy of cancer (2026). PMID: 42425715 ↗
L2PROSPECTIVE_COHORTCited in: Operative Techniques
[41]
Perrotta N, Coluccia A, Rossi F et al.. “Pharmacoeconomic Analysis of Osimertinib Compared to Earlier-Generation EGFR Inhibitors in EGFR-Mutated NSCLC: A Systematic Review.” Cancer medicine (2026). PMID: 42484063 ↗
L2SR_COHORTCited in: Fertility-Sparing Surgery
[42]
Lu R, Lin A, Jiang A et al.. “An interpretable multi-task whole-slide histopathology AI model for non-small cell lung cancer: Cross-cohort generalisation, spatial attention-transcriptomic integration, and molecular-immune profiling.” Clinical and translational medicine (2026). PMID: 42494157 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[43]
Yuan T. “Safety-aware AI for NSCLC trial pre-screening: a comparative proof-of-concept study of rule-based, single-agent, and multi-agent approaches.” International journal of medical informatics (2026). PMID: 42485959 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[44]
Homeniuk A, Syed A, Atrash A. “Survival Outcomes Associated With Prolonged Pembrolizumab After Definitive Chemoradiation for Non-small Cell Lung Cancer.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2026). PMID: 42476036 ↗
L4PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[45]
Li L, Liu Y, Wu Z et al.. “Internal Validity-Gated Dual Weighting: Toward Target Validity in the Synthesis of Randomized Controlled Trials and Real-World Studies.” Journal of evidence-based medicine (2026). PMID: 42483848 ↗
L1RCTCited in: Fertility-Sparing Surgery
[46]
Mastrantoni L, Vitale A, Russo J et al.. “Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.” Journal of the National Cancer Institute (2026). PMID: 42477876 ↗
L1RCTCited in: Fertility-Sparing Surgery
[47]
Izadpanah K, Rezaei M, Nejadghaderi SA et al.. “Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC): A Systematic Review.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42486074 ↗
L2SR_COHORTCited in: Fertility-Sparing Surgery
[48]
Chen W, Liang Y, Hou Q et al.. “Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer.” Frontiers in immunology (2026). PMID: 42495622 ↗
L3COHORTCited in: Fertility-Sparing Surgery
[49]
Du X, Luo X, Zhang H et al.. “Price trend, clinical benefit and within-class competition of drugs for metastatic Non-small cell lung cancer in China: a retrospective cohort study.” The Lancet regional health. Western Pacific (2026). PMID: 42495089 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[50]
Zhang Z, Tao X, Ju H et al.. “Adding local gyro-knife radiotherapy to EGFR-TKI improves outcomes in EGFR-mutant NSCLC.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42492466 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[51]
Hansford RLW, Davis LE, Griffiths R et al.. “Receipt of cancer care among stage IV non-small-cell lung cancer patients with and without intellectual or developmental disabilities: A population-based retrospective cohort study.” Palliative medicine (2026). PMID: 42490651 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[52]
Liu D, Yang S, Chen Y et al.. “Precision Stereotactic Body Radiotherapy for Ultra-Central NSCLC: Tailored Margins Reduce Toxicity Without Compromising Tumor Control.” MedComm (2026). PMID: 42488704 ↗
L3COHORTCited in: Fertility-Sparing Surgery
[53]
Lee JH, Song HH, Gu BM et al.. “Single-port robotic segmentectomy using the da Vinci SP system for non-small cell lung cancer.” Frontiers in surgery (2026). PMID: 42482943 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[54]
Morita S, Mimae T, Kudo Y et al.. “Local Control by Mediastinal Lymph-Node Dissection in Stage I Non-Small-Cell Lung Cancer.” Interdisciplinary cardiovascular and thoracic surgery (2026). PMID: 42479154 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[55]
Nakatsui M, Nishida Y, Nozue S et al.. “Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer.” Drugs - real world outcomes (2026). PMID: 42489799 ↗
L4COHORTCited in: Fertility-Sparing Surgery
[56]
Hodroj MH, Numan H, El-Halabi L et al.. “Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon.” JCO global oncology (2026). PMID: 42485593 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery
[57]
Zhang L, Huang L, Huang D et al.. “Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).” MedComm (2026). PMID: 42488708 ↗
L2NON_RANDOMIZED_TRIALCited in: Fertility-Sparing Surgery
[58]
Jones S, Falchook G, Graff S et al.. “A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.” The oncologist (2026). PMID: 42485262 ↗
L2NON_RANDOMIZED_TRIALCited in: Fertility-Sparing Surgery
[59]
Skoulidis F, Jabbour SK, Garon EB et al.. “Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 42485106 ↗
L2NON_RANDOMIZED_TRIALCited in: Fertility-Sparing Surgery
[60]
Abele JT, Allred K, Clare T et al.. “Lymphoscintigraphy in early-stage non-small cell lung cancer with technetium-99m nanocolloids and hybrid SPECT/CT: a pilot project.” Annals of nuclear medicine (2014). PMID: 24557659 ↗
L4RCTCited in: Sentinel Lymph Node Mapping
[61]
Hachey KJ, Digesu CS, Armstrong KW et al.. “A novel technique for tumor localization and targeted lymphatic mapping in early-stage lung cancer.” The Journal of thoracic and cardiovascular surgery (2017). PMID: 28274559 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping
[62]
Eo JS, Kim HK, Kim S et al.. “Gallium-68 neomannosylated human serum albumin-based PET/CT lymphoscintigraphy for sentinel lymph node mapping in non-small cell lung cancer.” Annals of surgical oncology (2014). PMID: 25155392 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping
[63]
Nomori H, Mori T, Ikeda K et al.. “Segmentectomy for selected cT1N0M0 non-small cell lung cancer: a prospective study at a single institute.” The Journal of thoracic and cardiovascular surgery (2012). PMID: 22502969 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping
[64]
Dalmeijer SWR, Zweedijk BE, Boldewijn DF et al.. “Evaluating the utility of ICG-based NIR imaging for small intestine neuroendocrine tumors: Challenges and the need for tumor-specific tracers.” Surgical oncology (2026). PMID: 42150271 ↗
L4PROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[65]
Digesu CS, Hachey KJ, Gilmore DM et al.. “Long-term outcomes after near-infrared sentinel lymph node mapping in non-small cell lung cancer.” The Journal of thoracic and cardiovascular surgery (2017). PMID: 29248292 ↗
L4PHASE_1_TRIALCited in: Sentinel Lymph Node Mapping
[66]
Gilmore DM, Khullar OV, Jaklitsch MT et al.. “Identification of metastatic nodal disease in a phase 1 dose-escalation trial of intraoperative sentinel lymph node mapping in non-small cell lung cancer using near-infrared imaging.” The Journal of thoracic and cardiovascular surgery (2013). PMID: 23790404 ↗
L4PHASE_1_TRIALCited in: Sentinel Lymph Node Mapping
[67]
Lilburn P, Kwan J, Williamson J et al.. “Endobronchial indocyanine green instillation to identify the intersegmental plane for successful segmentectomy.” Respirology case reports (2023). PMID: 37342249 ↗
L1RCTCited in: Sentinel Lymph Node Mapping
[68]
Ost DE, Niu J, Elting LS et al.. “Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.” Chest (2014). PMID: 24091637 ↗
L3RETROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[69]
Kim HK, Kim S, Sung HK et al.. “Comparison between preoperative versus intraoperative injection of technetium-99 m neomannosyl human serum albumin for sentinel lymph node identification in early stage lung cancer.” Annals of surgical oncology (2011). PMID: 22143575 ↗
L4COHORTCited in: Sentinel Lymph Node Mapping
[70]
Browne IL, Patel YS, Hanna NM et al.. “Three-dimensional virtual lung reconstruction in robotic segmentectomy: A safety and feasibility trial.” JTCVS techniques (2024). PMID: 39991293 ↗
L4PROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[71]
Bae SY, Kim DH, Yun T et al.. “Long-Term Outcomes of Indocyanine Green Versus Inflation-Deflation for Intersegmental Plane Identification in Segmentectomy for Early-Stage Lung Cancer.” Interdisciplinary cardiovascular and thoracic surgery (2026). PMID: 42386676 ↗
L3COHORTCited in: Sentinel Lymph Node Mapping
[72]
Ter Woerds DKM, Verhoeven RLJ, van der Heide SM et al.. “Feasibility of intraoperative indocyanine green injection to identify lymph nodes at risk of metastatic disease for early-stage lung cancer.” JTCVS techniques (2025). PMID: 40814677 ↗
L4COHORTCited in: Sentinel Lymph Node Mapping
[73]
Li Y, Cao Y, Chen Y et al.. “Comparison of watershed analysis with indocyanine green fluorescence staining and modified inflation-deflation method in single-port thoracoscopic complex pulmonary segmentectomy.” Journal of thoracic disease (2024). PMID: 39678874 ↗
L4RETROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[74]
Wollbrett C, Seitlinger J, Stasiak F et al.. “Clinicopathological factors associated with sentinel lymph node detection in non-small-cell lung cancer.” Journal of cardiothoracic surgery (2024). PMID: 38504315 ↗
L4COHORTCited in: Sentinel Lymph Node Mapping
[75]
Rudondy Q, Frey S, Bentellis I et al.. “Impact of indocyanine green on prolonged air leak in minimally invasive segmentectomy.” Thoracic cancer (2024). PMID: 38494909 ↗
L3COHORTCited in: Sentinel Lymph Node Mapping
[76]
Seitlinger J, Stasiak F, Piccoli J et al.. “What is the appropriate "first lymph node" in the era of segmentectomy for non-small cell lung cancer?” Frontiers in oncology (2023). PMID: 36776360 ↗
L4RETROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[77]
Wu Z, Zhang L, Zhao XT et al.. “Localization of subcentimeter pulmonary nodules using an indocyanine green near-infrared imaging system during uniportal video-assisted thoracoscopic surgery.” Journal of cardiothoracic surgery (2021). PMID: 34362399 ↗
L4COHORTCited in: Sentinel Lymph Node Mapping
[78]
Yotsukura M, Okubo Y, Yoshida Y et al.. “Indocyanine green imaging for pulmonary segmentectomy.” JTCVS techniques (2021). PMID: 34318180 ↗
L4RETROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[79]
Mitsos S, Panagiotopoulos N, Patrini D et al.. “Is systematic lymph node dissection mandatory or is sampling adequate in patients with stage I non-small-cell lung cancer?” Interactive cardiovascular and thoracic surgery (2019). PMID: 30496413 ↗
L3RETROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping
[80]
Ettinger DS, Wood DE, Aisner DL et al.. “NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37015337 ↗
L1GUIDELINECited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[81]
Lu S, Ahn MJ, Reungwetwattana T et al.. “Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39289145 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[82]
Daly ME, Singh N, Ismaila N et al.. “Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34936470 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[83]
Goss GD, Darling GE, Westeel V et al.. “Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41529222 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[84]
Kenmotsu H, Yamamoto N, Yamanaka T et al.. “Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32407216 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[85]
Wu YL, Hochmair M, Yang Y et al.. “Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicine (2026). PMID: 42223087 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[86]
Le Pechoux C, Pourel N, Barlesi F et al.. “Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.” The Lancet. Oncology (2021). PMID: 34919827 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[87]
Rosell R, Carcereny E, Gervais R et al.. “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.” The Lancet. Oncology (2012). PMID: 22285168 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[88]
Douillard JY, Rosell R, De Lena M et al.. “Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.” The Lancet. Oncology (2006). PMID: 16945766 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[89]
Zhang L, Zhang X, Wu L et al.. “Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 41539318 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria)
[90]
Bendixen M, Jørgensen OD, Kronborg C et al.. “Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.” The Lancet. Oncology (2016). PMID: 27160473 ↗
L1RCTCited in: Intraoperative Considerations and Complications
[91]
Spigel DR, Hainsworth JD, Yardley DA et al.. “Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19901100 ↗
L2NON_RANDOMIZED_TRIALCited in: Intraoperative Considerations and Complications
[92]
Bertoglio P, Gallina FT, Balzani E et al.. “Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42000405 ↗
L1SR_MA_RCTCited in: Intraoperative Considerations and Complications
[93]
Chang JY, Verma V, Li M et al.. “Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.” JAMA oncology (2017). PMID: 28727865 ↗
L2NON_RANDOMIZED_TRIALCited in: Intraoperative Considerations and Complications
[94]
Socinski MA, Stinchcombe TE, Moore DT et al.. “Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23045594 ↗
L4PHASE_1_TRIALCited in: Intraoperative Considerations and Complications
[95]
Lin YQ, Yang MZ, Cai JS et al.. “Beware of the plateau trap: a multidimensional analysis redefining the learning curve of robotic lobectomy in non-small cell lung cancer.” Journal of robotic surgery (2026). PMID: 42322386 ↗
L2PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[96]
Çelik B, İşevi C, Pirzirenli MG et al.. “Impact of Smoking Cessation Duration on Postoperative Complications in Lung Cancer Surgery.” The Journal of surgical research (2026). PMID: 42241832 ↗
L2PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[97]
Mazzali C, Buzzoni C, Grignani F et al.. “Robotic vs thoracoscopic vs open lobectomy and segmentectomy for lung cancer: a multicenter cohort study in the ATS of Milan.” Journal of robotic surgery (2026). PMID: 42237053 ↗
L2PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[98]
Wang Z, Gonzalez-Rivas D, Yu J et al.. “Uniportal Robotic-Assisted Sleeve Resections in a High-Volume Centre: Technique and Results.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 42102244 ↗
L2PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[99]
Yoon DK, Jung W, Jeon JH et al.. “Early outcomes of subcostal four-arm robotic pulmonary resection and mediastinal lymph node dissection for non-small cell lung cancer.” Journal of robotic surgery (2026). PMID: 41572024 ↗
L4PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[100]
Fraile Olivero CA, Sotillo Valenzuela L, Albarrán Vidal V et al.. “Fissios and postoperative complications (FPoC trial): a multicentre, randomised, controlled clinical trial.” BMJ open respiratory research (2026). PMID: 42303312 ↗
L1RCTCited in: Intraoperative Considerations and Complications
[101]
Tsukamoto Y, Nakada T, Watanabe Y et al.. “Chronic pleural effusion one year after lung cancer surgery is associated with non-cancer mortality and postoperative nutritional decline.” Surgical oncology (2026). PMID: 42235333 ↗
L4COHORTCited in: Intraoperative Considerations and Complications
[102]
Madeka I, Noueihed K, Woodroof J et al.. “Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection.” JAMA network open (2026). PMID: 42223938 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[103]
Mugutso E, Freund O, Pitrou I et al.. “Blood eosinophil counts and postoperative outcomes in early-stage lung cancer: a retrospective cohort study.” Respiratory research (2026). PMID: 42067843 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[104]
Huang L, Huang X, Zhou Y et al.. “Robotic-assisted versus video-assisted thoracoscopic anatomical pulmonary resection in elderly patients with lung cancer: A propensity score-matched comparison of short-term outcomes.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42061191 ↗
L3COHORTCited in: Intraoperative Considerations and Complications
[105]
Petroncini M, Bertoglio P, Garelli E et al.. “Safe transition to robotics: How an established program on vats shapes postoperative outcomes in lung resection.” Journal of robotic surgery (2026). PMID: 41851556 ↗
L3COHORTCited in: Intraoperative Considerations and Complications
[106]
Seyoum N, Tohmasi S, Eaton DB et al.. “The impact of frailty on postoperative outcomes of veterans with stage I non-small cell lung cancer.” Surgery (2026). PMID: 41679123 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications
[107]
Ferreira V, Minnella EM, Awasthi R et al.. “Multimodal Prehabilitation for Lung Cancer Surgery: A Randomized Controlled Trial.” The Annals of thoracic surgery (2020). PMID: 33321089 ↗
L1RCTCited in: Postoperative Recovery and ERAS
[108]
Tanaka F, Yokomise H, Soejima T et al.. “Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.” The Annals of thoracic surgery (2018). PMID: 29890150 ↗
L2RCT_PHASE2Cited in: Postoperative Recovery and ERAS
[109]
Cascone T, Gold KA, Swisher SG et al.. “Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.” The Annals of thoracic surgery (2017). PMID: 29217088 ↗
L2RCT_PHASE2Cited in: Postoperative Recovery and ERAS
[110]
Salama M, Mueller MR. “Enhanced recovery in lung surgery: coaxial versus conventional chest drains following video-assisted thoracoscopic surgery lobectomy-a prospective randomized trial.” Journal of thoracic disease (2025). PMID: 41376917 ↗
L1RCTCited in: Postoperative Recovery and ERAS
[111]
Cui Z, Zhang Y, Xu C et al.. “Comparison of the results of two chest tube managements during an enhanced recovery program after video-assisted thoracoscopic lobectomy: A randomized trial.” Thoracic cancer (2019). PMID: 31475791 ↗
L1RCTCited in: Postoperative Recovery and ERAS
[112]
Huang FF, Yang Q, Zhang J et al.. “A self-efficacy enhancing intervention for pulmonary rehabilitation based on motivational interviewing for postoperative lung cancers patients: modeling and randomized exploratory trial.” Psychology, health & medicine (2018). PMID: 29384705 ↗
L1RCTCited in: Postoperative Recovery and ERAS
[113]
Driessen EJ, Peeters ME, Bongers BC et al.. “Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: A systematic review.” Critical reviews in oncology/hematology (2017). PMID: 28477748 ↗
L4SR_COHORTCited in: Postoperative Recovery and ERAS
[114]
Cavalheri V, Burtin C, Formico VR et al.. “Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer.” The Cochrane database of systematic reviews (2019). PMID: 31204439 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS
[115]
Billiet C, Peeters S, Decaluwé H et al.. “Postoperative radiotherapy for lung cancer: Is it worth the controversy?” Cancer treatment reviews (2016). PMID: 27788387 ↗
L5NARRATIVE_REVIEWCited in: Postoperative Recovery and ERAS
[116]
Huang L, Kehlet H, Petersen RH. “Readmission after enhanced recovery video-assisted thoracoscopic surgery wedge resection.” Surgical endoscopy (2024). PMID: 38379006 ↗
L2PROSPECTIVE_COHORTCited in: Postoperative Recovery and ERAS
[117]
Wei W, Zhou J, Zhang Q et al.. “Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.” Cancer medicine (2020). PMID: 32100444 ↗
L2NON_RANDOMIZED_TRIALCited in: Postoperative Recovery and ERAS
[118]
Huang J, Wang PL, Xiao JZ et al.. “Development and validation of a predictive model for acute postoperative pain after thoracoscopic lobectomy in patients with NSCLC: a multicenter retrospective study.” International journal of surgery (London, England) (2025). PMID: 41217365 ↗
L3RETROSPECTIVE_COHORTCited in: Postoperative Recovery and ERAS
[119]
Huang L, Frandsen MN, Kehlet H et al.. “Days alive and out of hospital after video-assisted thoracoscopic surgery wedge resection in the era of enhanced recovery.” BJS open (2023). PMID: 38108464 ↗
L4COHORTCited in: Postoperative Recovery and ERAS
[120]
Boyce-Fappiano D, Nguyen QN, Chapman BV et al.. “Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.” Clinical lung cancer (2021). PMID: 33707003 ↗
L3COHORTCited in: Postoperative Recovery and ERAS
[121]
Forster C, Doucet V, Perentes JY et al.. “Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study.” Translational lung cancer research (2021). PMID: 33569296 ↗
L3COHORTCited in: Postoperative Recovery and ERAS
[122]
Boonyawan K, Gomez DR, Komaki R et al.. “Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.” International journal of radiation oncology, biology, physics (2018). PMID: 29976504 ↗
L4COHORTCited in: Postoperative Recovery and ERAS
[123]
Hong TH, Cho JH, Shin S et al.. “Extended sleeve lobectomy for centrally located non-small-cell lung cancer: a 20-year single-centre experience.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2018). PMID: 29408983 ↗
L4COHORTCited in: Postoperative Recovery and ERAS
[124]
Uda K, Matsui H, Fushimi K et al.. “Preoperative short-term plus postoperative physical therapy versus postoperative physical therapy alone for patients undergoing lung cancer surgery: retrospective analysis of a nationwide inpatient database.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2018). PMID: 28950377 ↗
L3RETROSPECTIVE_COHORTCited in: Postoperative Recovery and ERAS
[125]
Song Y, Li C, Fang Y et al.. “Inflammatory cytokine profile in non-small cell lung Cancer (NSCLC) patients during early enhanced recovery after surgery (ERAS) period and its relation to hospital length of stay.” Cytokine (2025). PMID: 40120149 ↗
L3CASE_CONTROLCited in: Postoperative Recovery and ERAS
[126]
Zheng T, Zhang B, Zhang X et al.. “The safety and feasibility of non-intubated versus intubated video-assisted thoracic surgery in NSCLC patients after neoadjuvant therapy: a propensity score matching study.” Journal of thoracic disease (2026). PMID: 42182783 ↗
L4COHORTCited in: Postoperative Recovery and ERAS
[127]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545176 ↗
L1GUIDELINECited in: Outcomes by Stage and Approach
[128]
Ettinger DS, Aisner DL, Wood DE et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30006423 ↗
L1GUIDELINECited in: Outcomes by Stage and Approach
[129]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404761 ↗
L1GUIDELINECited in: Outcomes by Stage and Approach
[130]
Grossman SA, Ellsworth S, Campian J et al.. “Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26483062 ↗
L2SR_COHORTCited in: Outcomes by Stage and Approach
[131]
Chow R, Lage DE, Williams GR et al.. “Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 34991068 ↗
L2SR_COHORTCited in: Outcomes by Stage and Approach
[132]
Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach
[133]
Ahn MJ, Tanaka K, Paz-Ares L et al.. “Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39250535 ↗
L1RCTCited in: Outcomes by Stage and Approach
[134]
Solomon BJ, Liu G, Felip E et al.. “Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38819031 ↗
L1RCTCited in: Outcomes by Stage and Approach
[135]
Leighl NB, Akamatsu H, Lim SM et al.. “Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38857463 ↗
L1RCTCited in: Outcomes by Stage and Approach
[136]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33872070 ↗
L1RCTCited in: Outcomes by Stage and Approach
[137]
Brahmer JR, Lee JS, Ciuleanu TE et al.. “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36223558 ↗
L1RCTCited in: Outcomes by Stage and Approach
[138]
Gadgeel S, Rodríguez-Abreu D, Speranza G et al.. “Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32150489 ↗
L1RCTCited in: Outcomes by Stage and Approach
[139]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30620668 ↗
L1RCTCited in: Outcomes by Stage and Approach
[140]
Waliany S, Roy SG, Pecci F et al.. “Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671458 ↗
L3RETROSPECTIVE_COHORTCited in: Outcomes by Stage and Approach
[141]
Bagley SJ, Talento S, Mitra N et al.. “Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085759 ↗
L3RETROSPECTIVE_COHORTCited in: Outcomes by Stage and Approach
[142]
Hoffner B, Leighl NB, Davies M. “Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.” Cancer treatment reviews (2020). PMID: 32078962 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach
[143]
Zhao Y, He Y, Wang W et al.. “Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.” The Lancet. Oncology (2024). PMID: 39159630 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach
[144]
Conforti F, Pala L, Bagnardi V et al.. “Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29778737 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach
[145]
Wang J, Lu S, Yu X et al.. “Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial.” ESMO open (2024). PMID: 39461775 ↗
L1RCTCited in: Outcomes by Stage and Approach
[146]
Carbone DP, Ciuleanu TE, Cobo M et al.. “Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.” ESMO open (2025). PMID: 40446626 ↗
L1RCTCited in: Outcomes by Stage and Approach